| Project/Area Number |
18591544
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | Shiga University of Medical Science |
|---|
Principal Investigator |
OZAKI Yoshitomo Shiga University of Medical Science, Department of Surgery, Assistant Professor (00378449)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TEZUKA Noriaki Shiga University of Medical Science, Department of Surgery, Associate Professor (40303771)
FUJINO Shozo Teikyo University, Department of Surgery, Professor (10209075)
澤井 聡 滋賀医科大学, 医学部, 助手 (60335172)
|
|---|
| Project Period (FY) |
2006 – 2007
|
| Project Status |
Completed (Fiscal Year 2007)
|
| Budget Amount *help |
¥3,920,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥420,000)
Fiscal Year 2007: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2006: ¥2,100,000 (Direct Cost: ¥2,100,000)
|
|---|
| Keywords | Immunotherapy / 90K / lung cancer / CTL / Dendritic cell |
|---|
| Research Abstract |
We have reported that tumor associated antigen, 90K/Mac-2 binding protein was highly expressed in lung cancer and that 90K-specific CTLs that were induced using 90K derived epitope showed cytolytic activities against 90K-positive cancer cells. In order to achieve sufficient therapeutic potency, we established matured/activated dendritic cells (DCs) with more potent antigen presenting capacity. These DCs could elicit more efficient tumor antigen-specific cytotoxic T lymphocytes (CTLs) from patients with metastatic cancer as stimulators than PBMCs. Additionally ; we analyzed anti- tumor DNA vaccine strategy using pigeon cytochrome c-derived peptides (Pan-IA), which bind broad ranges of MHC class II molecules efficiently, activate T helper (Th) function in mice. In this model, Pan-IA-loaded DCs augmented antitumor immunity in mice immunized with ovalbumin (OVA) antigen DNA. This novel vaccination strategy contributes to the development of DC-based cancer vaccines specific for 90K antigen.
|
